HC Wainwright Begins Coverage on SAB Biotherapeutics (NASDAQ:SABS)

Research analysts at HC Wainwright began coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 415.46% from the stock’s current price.

Separately, Chardan Capital cut their target price on SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $12.20.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $1.94 on Wednesday. The company has a market capitalization of $18.03 million, a P/E ratio of -0.52 and a beta of 0.47. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. The stock has a 50 day moving average price of $1.51 and a two-hundred day moving average price of $2.52.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Friday, May 9th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.44. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Trading of SAB Biotherapeutics

Several large investors have recently added to or reduced their stakes in SABS. HB Wealth Management LLC lifted its holdings in SAB Biotherapeutics by 10.9% in the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock worth $358,000 after buying an additional 25,800 shares during the period. Geode Capital Management LLC increased its stake in shares of SAB Biotherapeutics by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after purchasing an additional 12,692 shares in the last quarter. Diadema Partners LP purchased a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $114,000. Silver Oak Securities Incorporated purchased a new position in shares of SAB Biotherapeutics during the first quarter valued at approximately $30,000. Finally, Northern Trust Corp bought a new stake in shares of SAB Biotherapeutics in the 4th quarter worth approximately $43,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.